Cardiff Oncology, Inc. CRDF 深 滬
已收盤 07-02 16:00:00 美东时间
1.27
-0.020
-1.55%
華盛通- 最 高1.31
- 今 開1.27
- 成交量 132.14万股
- 最 低 1.20
- 昨 收 1.29
- 總市值 8682.98万
- 52周最高 4.555
- 市盈率 靜 --
- 換手率 1.93%
- 52周最低 1.16
- 委 比 -94.75%
- 總股本 6836.99万
- 歷史最高 977.76
- 量 比 0.65
- 振 幅 8.53%
- 歷史最低 0.701
- 每 手 1
- 風險率 0.68%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元
火爆！24家大行集体上调派拓网络目标价，最高370美元；大摩上调美光目标价从520美元升至1050美元；犹他美容(ULTA)惨遭12家大行下调目标价>>
06-04 11:36
NMS Informs Cardiff Oncology Of Agreement Termination On May 27, 2026; NMS Alleges Cardiff Oncology Breached Agreement Over Cardiff Patents Inventorship; NMS Alleges Failure By Cardiff Oncology To Use Commercially Reasonable Efforts For Onvansertib; Cardiff Oncology States NMS Termination Notice Is Ineffective And Will Continue Under Agreement
https://www.sec.gov/ix?doc=/Archives/edgar/data/0001213037/000119312526248711/crdf-20260527.htm
05-30 05:16
Cardiff Oncology Sues Nerviano As Analyst Backs Onvansertib Defense
Cardiff Oncology sued Nerviano Medical Sciences over onvansertib licensing claims as analysts backed Cardiff's legal stance.
05-21 02:11
Cardiff Oncology Q1 EPS $(0.18) Misses $(0.15) Estimate, Sales $41.000K Miss $85.000K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.18) per share which missed the analyst consensus estimate of $(0.15) by 20 percent. This is a 10 percent increase over losses of $(0.20) per share from the
05-15 04:59
Cardiff Oncology To Present Preclinical Data On PLK1 Inhibitor Onvansertib In Combination With HER2-Targeted ADC, T-DXd, At AACR Annual Meeting 2026
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, will present new preclinical data in a poster at the American
04-18 04:04
Cardiff Oncology Appoints Mani Mohindru As President And Chief Executive Officer; Josh Muntner Appointed As CFO
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced the appointment of Mani Mohindru, PhD, as
04-10 04:03
Cardiff Oncology To Host Key Opinion Leader Webinar To Discuss Emergent Treatment Landscape In First-Line RAS-Mutated Metastatic Colorectal Cancer On March 25
Cardiff Oncology, Inc. (NASDAQ:CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will host a key opinion
03-20 19:03
美股大行评级 | 大摩将应用材料目标价升至432美元；潜在涨幅200.0%！维尔生物科技获巴克莱升目标价至30美元，维持"超配"评级
今日重点评级关注：巴克莱：维持Vir Biotechnology"超配"评级，目标价从26美元升至30美元；巴克莱：维持Iovance Biotherapeutics"超配"评级，目标价从10美元升至11美元
02-26 09:30
Piper Sandler Maintains Overweight on Cardiff Oncology, Lowers Price Target to $6
Piper Sandler analyst Edward Tenthoff maintains Cardiff Oncology (NASDAQ:CRDF) with a Overweight and lowers the price target from $10 to $6.
02-25 22:40
Cardiff Oncology Q4 EPS $(0.11) Beats $(0.20) Estimate, Sales $243.000K Beat $105.556K Estimate
Cardiff Oncology (NASDAQ:CRDF) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.20) by 44.72 percent. This is a 47.62 percent increase over losses of $(0.21) per share from
02-25 05:59
